Next Article in Journal / Special Issue
Exome Sequencing in Fetuses with Structural Malformations
Previous Article in Journal
Hepatic Atypical Protein Kinase C: An Inherited Survival-Longevity Gene that Now Fuels Insulin-Resistant Syndromes of Obesity, the Metabolic Syndrome and Type 2 Diabetes Mellitus
Previous Article in Special Issue
The Psychological Challenges of Replacing Conventional Karyotyping with Genomic SNP Array Analysis in Prenatal Testing
J. Clin. Med. 2014, 3(3), 741-746; doi:10.3390/jcm3030741
Communication

Pregnancy Loss Following Amniocentesis or CVS Sampling—Time for a Reassessment of Risk

1,*  and 2,3
1 Guy's and St. Thomas' NHS Foundation Trust and King's College, London SE1 9RT, UK 2 Medway Maritime Hospital, Gillingham, Kent ME7 5NY, UK 3 King's College Hospital, Denmark Hill, London SE5 9RS, UK
* Author to whom correspondence should be addressed.
Received: 31 March 2014 / Revised: 24 May 2014 / Accepted: 29 May 2014 / Published: 8 July 2014
(This article belongs to the Special Issue Prenatal Genetic Screening and Diagnosis-Part 2)
View Full-Text   |   Download PDF [165 KB, uploaded 8 July 2014]

Abstract

Risk of procedure-related pregnancy loss is currently widely quoted in the UK as 1% for amniocentesis and 1.5% for chorionic villus sampling. Published data suggest that these risk figures are out of date and inaccurate, and that new guidelines are required for pre-test counseling. It is our opinion that accurate and evidence-based information concerning miscarriage risk is vital when counseling women, as exaggeration of this risk may deter women from testing, or cause unjustified remorse if a miscarriage ensues. It is also essential that health-care economists are aware of the up-to-date evidence on “procedure-related risk” when applying risk-benefit analysis to assess new technology for non-invasive screening.
Keywords: miscarriage; procedure-related pregnancy loss; amniocentesis; chorionic villus sampling (CVS); non-invasive prenatal testing; cell free fetal DNA miscarriage; procedure-related pregnancy loss; amniocentesis; chorionic villus sampling (CVS); non-invasive prenatal testing; cell free fetal DNA
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Ogilvie, C.; Akolekar, R. Pregnancy Loss Following Amniocentesis or CVS Sampling—Time for a Reassessment of Risk. J. Clin. Med. 2014, 3, 741-746.

View more citation formats

Related Articles

Article Metrics

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert